Clinical Trial: NCT01176916 - My Cancer Genome

NCT01176916

Description:

Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen & are switched to Aromasin® for completion of a total of 5 consecutive years of adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with clinical trial waive. While Aromasin® has been used in China for adjuvant therapy of breast cancer since then, there is currently lack of systematic collection and analysis for the efficacy and safety data of Aromasin® adjuvant setting in Chinese population. The Aromasin® Interventional Study is being proposed to collect data systematically and to assess the efficacy and safety of Aromasin® adjuvant setting in Chinese population.

Related Conditions:

Breast Carcinoma

Recruiting Status:

Completed

Phase:

Phase 4

URL:

https://clinicaltrials.gov/show/NCT01176916

Trial Eligibility

Document

Title

Brief Title: Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Official Title: A PROSPECTIVE PRAGMATIC CLINICAL TRIAL OF CHINA EARLY INVASIVE BREAST CANCER PATIENTS RECEIVING ADJUVANT THERAPY WITH AROMASIN

Clinical Trial IDs

ORG STUDY ID: A5991093
SECONDARY ID: NRA5990043
NCT ID: NCT01176916

Conditions

Breast Neoplasms

Interventions

Drug	Synonyms	Arms
Aromasin (exemestane)		A

Purpose

Detailed Description

      This is interventional study and single arm study. N/A

Trial Arms

Name	Type	Description	Interventions
A	Experimental		Aromasin (exemestane)

Eligibility Criteria

        Inclusion Criteria:

          -  Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.

          -  ER positive.

          -  The patient must be postmenopausal woman.

          -  The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will
             switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will
             necessarily precede and will be independent of the decision to enroll patients in the
             study).

        Exclusion Criteria:

          -  Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving
             Aromasin® treatment, there is evidence of a local relapse or distant metastasis of
             breast cancer, or a second primary cancer.

          -  Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase
             inhibitors (not Aromasin®).

Maximum Eligible Age:	N/A
Minimum Eligible Age:	18 Years
Eligible Gender:	Female
Healthy Volunteers:	No

Primary Outcome Measures

Measure:	Time-to-Event
Time Frame:	2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
Safety Issue:
Description:	An event was defined as the earliest occurrence of any of the following: 1) Loco-regional/distant recurrence of the primary breast cancer (BC) (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause.

Secondary Outcome Measures

Measure:	Percentage of Participants Experiencing Each Event
Time Frame:	2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
Safety Issue:
Description:	An event was defined as the following: 1) Loco-regional/distant recurrence of the primary breast cancer (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause.

Measure:	Incidence Rate of Each Event
Time Frame:	2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
Safety Issue:
Description:	Incidence rate (per annum) of the event was defined as a ratio of the number of events and the total exposure time (in years) to Aromasin therapy.

Measure:	Hazard Ratio: the Relationship Between (Human Epidermal Growth Factor Receptor 2) HER2 Status and Time-to-Event
Time Frame:	2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
Safety Issue:
Description:	A Cox proportional hazards regression model was used to evaluate the relationship between HER2 status level (binary) and time-to-event (Positive vs Negative). The method for selecting factors for the Cox regression model was based on significant results at univariate analysis and the clinical judgement for the multivariate model. Stepwise method was used for the selection of final independent variables. The criteria for stepwise selection were pentry = 0.25 and pstay = 0.15.

Measure:	Harzard Ratio: the Relationship Between Multiple Disease Variables and Time-to-Event
Time Frame:	2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
Safety Issue:
Description:	A Cox proportional hazards regression model with stepwise selection was used to evaluate the influence of multiple disease variables on the time-to-event. The disease variables in the initial model included Eastern Cooperative Oncology Group [ECOG] performance status at diagnosis; and Tumor, Lymph Node and Metastasis [TNM] stage at initial diagnosis. The ECOG Performance Status describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability. ECOG performance status at diagnosis level included 0, 1, 2, 3 and 4, with Level 0 as the best status and Level 4 as the worst. The TNM system helps describe the size of cancer tumor and the extent to which it spreads to nearby tissues/distant parts of the body. TNM stage at initial diagnosis level included 1 (Stage I), 2 (Stage IIA), 3 (Stage IIB), 4 (Stage IIIA), 5 (Stage IIIB) and 6 (Stage IIIC), with Level 1 as the best status and Level 6 as the worst.

Measure:	Number of Participants With Discontinuation Due to Adverse Events (AEs)
Time Frame:	2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
Safety Issue:
Description:	Participants permanently discontinued from the study due to AEs were counted for this outcome measure. An AE is any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The number of participants with discontinuation due to all-causality and treatment-related AEs are reported below. Treatment-related AEs were determined by the investigator.

Measure:	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame:	2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
Safety Issue:
Description:	All-causality TEAEs were counted for this outcome measure. TEAE is defined as an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. The number of participants with all-causality and treatment-related TEAEs are reported below. Treatment-related TEAEs were determined by the investigator.

Details

Phase:	Phase 4
Primary Purpose:	Interventional
Overall Status:	Completed
Lead Sponsor:	Pfizer

Trial Keywords

breast cancer
Aromasin
adjuvant chemotherapy
endocrine therapy

Last Updated

October 12, 2020

Clinical Trials /

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China